Patents Assigned to Bach Pharma, Inc.
-
Patent number: 9968602Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: GrantFiled: February 11, 2013Date of Patent: May 15, 2018Assignee: BACH PHARMA, INC.Inventors: Mark O. Henry, William S. Lynn
-
Patent number: 9732043Abstract: The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione (for example, 5-amino-2,3-dihydrophthalazine-1,4-dione) for administration to a human or animal. The manufacturing methods identify and isolate starting materials (for example, 3-nitrophthalic acid), and prepare intermediate products (for example, 3-nitrophthalhydrazide), which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final phthalazinedione products. In an embodiment, a solution of 3-nitrophthalhydrazide and sodium hydroxide in water is prepared and hydrogenated to yield 5-amino-2,3-dihydrophthalazine-1,4-dione.Type: GrantFiled: February 6, 2015Date of Patent: August 15, 2017Assignee: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Patent number: 9358225Abstract: Ataxia-telangiectasia (A-T) is a progressive degenerative disorder that results in major neurological disability. In A-T patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive Purkinje and granular cell loss. We have previously identified an increase in phospho-p38MAPK levels, which was accompanied by downregulation of Bmi-1 and upregulation of p21, as key components of the mechanism causing defective proliferation of neural stem cells (NSCs) isolated from subventricular zone (SVZ) of Atm-null mice. Our results demonstrate that restoration of NSCs by pharmacologic inhibition of p38MAPK signaling has the potential to treat neurological defects of A-T. This study provides new insights into the therapeutic strategy targeting NSCs rather than replacing impaired neurons not only for A-T, but for other neurodegenerative disorders as well.Type: GrantFiled: March 17, 2014Date of Patent: June 7, 2016Assignee: Bach Pharma, Inc.Inventor: Paul K. Y. Wong
-
Patent number: 8895555Abstract: Provided herein are methods of treating intestinal diseases or inflammatory conditions, including HIV-AIDS, in which oxidative stress is a triggering or exacerbating factor by administering GVT to a patient suffering from the condition such that the condition is treated.Type: GrantFiled: February 19, 2010Date of Patent: November 25, 2014Assignee: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Publication number: 20100255077Abstract: Provided herein are methods of treating intestinal diseases or inflammatory conditions, including HIV-AIDS, in which oxidative stress is a triggering or exacerbating factor by administering GVT to a patient suffering from the condition such that the condition is treated.Type: ApplicationFiled: February 19, 2010Publication date: October 7, 2010Applicant: BACH PHARMA, INC.Inventors: Mark O. HENRY, Williams S. LYNN
-
Publication number: 20100222584Abstract: The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione for administration to a human or animal. The manufacturing methods identify and isolate starting materials, and prepare intermediate products, which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final phthalazinedione products.Type: ApplicationFiled: February 5, 2010Publication date: September 2, 2010Applicant: BACH PHARMA, INC.Inventors: Mark O. HENRY, William S. LYNN
-
Publication number: 20100086531Abstract: Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: ApplicationFiled: September 23, 2009Publication date: April 8, 2010Applicant: BACH PHARMA INC.Inventors: Mark O. Henry, William S. Lynn
-
Patent number: 7691819Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: GrantFiled: February 4, 2008Date of Patent: April 6, 2010Assignee: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Publication number: 20090036411Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: ApplicationFiled: March 7, 2008Publication date: February 5, 2009Applicant: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Publication number: 20090018137Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: ApplicationFiled: February 4, 2008Publication date: January 15, 2009Applicant: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Patent number: 7326690Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: GrantFiled: August 8, 2005Date of Patent: February 5, 2008Assignee: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn
-
Publication number: 20070142303Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: ApplicationFiled: January 30, 2007Publication date: June 21, 2007Applicant: Bach Pharma, Inc.Inventors: Mark Henry, William Lynn
-
Publication number: 20050288291Abstract: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.Type: ApplicationFiled: August 8, 2005Publication date: December 29, 2005Applicant: Bach Pharma, Inc.Inventors: Mark Henry, William Lynn
-
Patent number: 6953799Abstract: Phthalazine diones that function as intracellular redox modulators and buffers are used to treat stressed cells in various disease states in which the intracellular redox status is impaired. By optimal buffering of aberrant redox states, phthalazine diones enhance the cellular processes essential for survival and augment the conventional or other external therapies necessary for treatment. The phthalazine diones of the invention thus regulate cell growth, differentiation, or death to serve as essential adjunctive therapy for the stressed host in various disease states.Type: GrantFiled: October 30, 2002Date of Patent: October 11, 2005Assignee: Bach Pharma, Inc.Inventors: Mark O. Henry, William S. Lynn